Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

/PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of...

Related Keywords

China ,Amsterdam ,Noord Holland ,Netherlands ,Microtubule Synstatin ,Microtubule Syntansine ,Innovent Biologics ,Chong Kun Dang Pharma ,Lepu Biopharma ,Adimab Incyte ,Eli Lilly ,Prnewswire Synaffix ,Amgen ,Md Anderson Cancer Center ,Research At Innovent ,Innovent Biologics Inc ,Platform Technology ,Vice President ,Cancer Biology ,Mersana Therapeutics ,Shanghai Miracogen ,Kyowa Kirin ,Emergence Therapeutics ,Hummingbird Biosciences ,Sintilimab Injection ,Bevacizumab Injection ,Adalimumab Injection ,Rituximab Injection ,Pemigatinib Oral Inhibitor ,Ramucirumab Injection ,Selpercatinib Capsules ,Equecabtagene Autoleucel Injection ,Tafolecimab Injection ,Cancer Center ,Synaffix ,